RPS23 and neoplasm: Of note, this recombinant was purposely designed to achieve enhanced anti-tumor potency with a specific strategy—first, it was obtained starting from a clinical isolate (JS-1) displaying enhanced cell killing of an array of human tumor cell lines, as compared to laboratory strains (e.g., HSV-1 strain 17); second, its genome was also modified with the deletion of US12 (ICP47), as described above for G47Δ (see Section 2.1) to enhance replication, immunostimulation and tumor lysis.